ArticleFrontiers in endocrinology2026
Association between low-density lipoprotein cholesterol and frailty in adults aged ≥70 years: a cross-sectional study from Beijing, China.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Frailty becomes increasingly prevalent with advancing age and is influenced by multifactorial physiological and pathological processes. This study aimed to assess the current prevalence of frailty among adults aged ≥70 years and to investigate the association between low-density lipoprotein cholesterol (LDL-C) levels and frailty. Methods: A cross-sectional study was conducted on 218 adults aged 70 and above in Beijing, China, collecting data on their sociodemographic characteristics, lifestyle, comorbidities, and peripheral blood biomarkers. The FRAIL scale was used to measure frailty, and the association between LDL-C and frailty was examined using exploratory analyses that employed ordinal logistic regression, multiple linear regression, and restricted cubic splines (RCS). Stratified analyses were also conducted, dividing participants into subgroups based on polypharmacy, hypertension, diabetes mellitus, coronary heart disease, and alcohol status, to examine the association between LDL-C and frailty. Results: The mean age of participants was 77.5 ± 6.4 years. The prevalence of robust, pre-frailty, and frailty was 20.6%, 69.7%, and 9.6%, respectively. Adjusted ordinal logistic regression revealed a negative association between LDL-C and frailty (OR = 0.667, 95% CI = 0.489 to 0.909, P = 0.010). Multiple linear regression confirmed this association (β = -0.129, 95% CI = -0.245 to -0.012, P = 0.031). According to the RCS curve, the non-linear relationship between LDL-C and the level of frailty was not significant (P = 0.639). Stratified analyses demonstrated that LDL-C was significantly negatively associated with frailty in non-drinkers and in individuals without hypertension or diabetes mellitus. Conclusions: Pre-frailty is prevalent among older adults aged ≥70 years, and the relationship between LDL-C and frailty was negative. These findings suggest that individualized lipid management in older adults may need to account for frailty status.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.